Dr Andreas Nechansky received his PhD in the field of Molecular Biology from the University of Vienna. He started his academic career with two PostDoc positions at Novartis Vienna (1998−2000) and the Scripps Research Institute in La Jolla, US, (2001−2002) working in the field of antibody generation/characterization. In 2003, he joined the Austrian Biotech company Igeneon as Project Leader for three pre-clinical assets.
In 2005 he was promoted to Head Analytical Development. In 2006 he Co-founded VelaLabs and from then on served as COO and for 3 years as Head of Quality control.
In 2015 he joined the Biosimilar company Eden as VP Analytical Operations and moved to Taiwan. He was responsible for setting up all analytical assays required for biologics comparability studies. In 2019 he re-located back to Austria where he became Site Manager and subsequently Managing Director of ABF Pharmaceutical Services. He is a certified EU Qualified Person and has published 20+ analytical papers in peer reviewed journals.
With this background and knowledge of analytical services, he is a perfect fit checking a lot of boxes. He can rely on a very competent team and broad collaboration within VelaLabs.
